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ABSTRACT
A myeloablative conditioning regimen incorporating daily intravenous busulfan, fludarabine, and 400 cGy
total-body irradiation was given before allogeneic stem cell transplantation (SCT) to 64 adults with acute
leukemia in first and second remission. Graft-versus-host disease (GVHD) prophylaxis included methotrexate,
cyclosporine A, and rabbit antithymocyte globulin (Thymoglobulin). For 31 matched related (MRD) and 33
alternate donor (AD) SCT the incidence of acute GVHD grade II-IV was 11%  6% versus 35%  9% (P 
.047), acute GVHD grade III-IV was 0% versus 10% 6% (P .09), and chronic GVHDwas 40% 9% versus
66%  9% (P  NS), respectively. Overall transplant-related mortality (TRM) was 3%  2%. Projected
disease-free (DFS) and overall survival (OS) at 3 years for acute myelogenous leukemia (AML) (n  36) are the
same at 83%  6%, and for acute lymphoblastic leukemia (ALL) (n  28) are 65%  10% and 78%  8%,
respectively. For MRD SCT DFS is 77%  9%, OS 87%  6%, for AD SCT the respective figures are 71% 
8% and 74%  8%. OS and DFS in patients without and with high-risk features are 100% versus 71%  7%
(P  .007) and 88%  8% versus 68%  7% (P  .04), respectively. This combination appears relatively well
tolerated, gives equivalent final outcomes from MRD and AD, and may be a reasonable alternative to
conventional myeloablative regimens.
© 2007 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (HSCT) after myeloablative conditioning is com-
only used to treat acute myelogenous leukemia
AML) and acute lymphoblastic leukemia (ALL). Re-
ults are signiﬁcantly better when patients are in com-
lete remission (CR), but there remains some contro-
ersy regarding which patients should be treated in
rst remission (CR1) [1-3]. The high transplant-re-
ated mortality (TRM) associated with myeloablative
CT limits the advantage conferred by lower relapse f
14ates than alternatives such as autologous transplanta-
ion and chemotherapy. Moreover, the long-term
orbidity, particularly that from chronic graft-versus-
ost disease (cGVHD), makes SCT less attractive if
here is no survival beneﬁt [4].
The challenge therefore is to develop myeloabla-
ive regimens that give effective cytoreduction but
ith low TRM. The additional antileukemic effect of
he graft (graft-versus-leukemia, GVL) should be
aintained while controlling morbidity and mortalityrom GVHD.
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SCT for Acute Leukemia in CR1 and CR2 815Thus far, no regimens have proved superior to
hose incorporating total-body irradiation (TBI) in
oth AML and ALL. However, the TBI doses used
commonly 1200 cGy or more in 6-8 fractions) have
igniﬁcant long-term toxicities, particularly in chil-
ren [5,6].
The widely used combination of busulfan (Bu) and
yclophosphamide (Cy) is effective in AML but less so
n ALL [7-19]. Intravenous Bu is better tolerated than
he oral form [20-22], but has not been fully evaluated
n comparison with TBI containing regimens in acute
eukemia. However, preliminary experience with an
ntravenous Bu and ﬂudarabine (Flu) combination has
hown impressive results in AML and myelodysplasia
MDS) [23]. The addition of 400 cGy TBI to a Flu/Bu
ombination with antithymocyte globulin (ATG) ap-
ears to reduce relapse rate in AML without increas-
ng toxicity [24]. In AML, it was ﬁrst used in patients
ith extramedullary disease and then applied to all
atients after more experience with the combination.
e have used this regimen in ALL throughout be-
ause of the reluctance to drop TBI entirely and a
esire to avoid the toxicity of full-dose TBI. We now
eport the results of this combination in AML and
LL in CR1 and CR2.
ATIENTS AND METHODS
This report includes patients with both ALL
nd AML transplanted between June 1999 and June
005. Outcomes are similar in these diseases with
his regimen and a combined analysis allows a more
ccurate evaluation of TRM. Patients in CR1 and
R2 receiving SCT from matched related donors
MRD) and alternate donors (unrelated and mis-
atched related donors, AD) are included as out-
omes and are similar with both donor types and
isease stages.
Details of the 64 patients are shown in Table 1.
atients were considered to be in CR if there were
5% blasts in the bone marrow regardless of other
riteria including cytopenias and evidence of resid-
al leukemia on karyotypic analysis or ﬂow cytom-
try.
Institutional inclusion criteria for allogeneic SCT
ncluded left ventricular ejection fraction 45%, pul-
onary function (DLCO, FEV1, and FVC) 45%
redicted, creatinine 150 mol/L, bilirubin, and
LT3 times normal and ECOG performance status
-2.
All patients and donors had high-resolution typing
or DR and DQ. Class I typing for A, B, and C was
one until 2001 at medium resolution, thereafter at
igh resolution. Four patients (1 AML, 3 ALL) may
herefore have had mismatched unrelated SCT re-
orded as fully matched. oBlood cells were used for all related donor SCT.
or unrelated donor (UD) transplants cell source was
ometimes determined by availability. Later in the
tudy a preference was expressed for blood cells as
hey became more available, and it seemed that cell
oses requested were more likely to be provided than
ith bone marrow. Target doses for blood cells were
.0 106 CD34 cells/kg and for bone marrow 3.0
08 nucleated cells/kg.
The preparative regimen comprised Flu 50 mg/m2
able 1. Patient and transplant details
AML % ALL %
umber 36 28*
atient age, years median
(range) 46 (20-60) 31 (18-63)
R2 12 33 5 18
ytogenetic risk group†
NA 5 14‡ 9 32
1 2 7§ 1
2 19 61 9 32
3 10 32 9 32
resenting white blood
cell count greater
than 25  109/L 20 56 6 21
retransplant platelet
count less than
100  109/L 7 19 1 4
inimal residual disease
on flow cytometry
&/or cytogenetics 0 0 5 18
econdary leukemia 3 8 1 4
ssociated myelodysplasia 3 8 0 0
igh-risk features 24 67 18¶ 64
ytomegalovirus antibody
positive recipient or
donor 25 69 16 57
ale 23 64 17 61
emale-male transplant 5 14 8 29
lternate donor 20 56 13 46
mismatched related 2 6 3 11
matched unrelated 13 36 9 32
mismatched unrelated 5 14 1 4
lood cell transplant 34 94 22 79
BI day 0 19 53 18 67
ays from CR to
transplant median
(range) 62 (9-196) 69 (7-203)
ollow-up of survivors,
months median
(range) 26 (12-66) 48 (12-73)
Includes two with lymphoblastic lymphoma (one T cell) and an-
other with T-ALL.
AML-low t(8:21), inv 16, t(15:17), high-complex karyotype, ab-
normalities of 5 & 7.
LL-high - t(9:22), t(4:11), 11q23 rearrangement.
% of total.
% of successful analyses.
One or more of CR2, associated MDS, high risk cytogenetics.
One or more of: CR2, presenting WBC 25  109/L, high risk
cytogenetics, minimal residual disease, prolonged induction
(3 mo).n days 6 to 2, intravenous Bu (Busulfex, PDL
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J. A. Russell et al.816harma, Fremont, CA) 3.2 mg/kg daily days5 to2
nclusive and TBI 200 cGy  2 on days 1 or 0. The
ay of TBI was determined by the capacity of the
adiation therapy department and other constraints of
he protocol, particularly the time at which stem cells
ecame available.
Supportive care was similar for all patients. No
rotective isolation was used [25]. Single donor plate-
ets were given to maintain counts 10  109/L and
ed cells to keep hemoglobin levels 80 g/L. Growth
actors were not given routinely. All patients received
wice weekly trimethoprim/sulfamethoxazole as pro-
hylaxis for P. carinii. Antibacterial prophylaxis was
iproﬂoxacin 500 mg twice daily until 2003 after
hich time no antibacterial antibiotics were given
outinely. Blood products were all from cytomegalo-
irus (CMV) seronegative donors. A policy of surveil-
ance for pp65 antigen and preemptive therapy with
anciclovir was used when donor and/or recipient
ere CMV antibody positive. Routine monitoring of
pstein-Barr virus (EBV) viral load was not done. The
cute GVHD (aGVHD) prophylaxis protocol in-
luded Cyclosporin A (CSA) orally or intravenously
wice daily to maintain blood levels between 150 and
00 mol/L. Methotrexate (MTX) was given at 15
g/m2 intravenously on days 1 and 10 mg/m2 on days
, 6, and 11. Folinic acid 5 mg intravenously or orally
as started 24 hours after each MTX dose and con-
inued every 6 hours until 12 hours before the next
ose [26]. In addition, all patients were given rabbit
TG (Thymoglobulin, Genzyme, Cambridge, MA)
.5 mg/kg intravenously in divided doses over 3 days.
ach dose was given as a continuous infusion over 4-8
ours. To reduce reactions, the ﬁrst dose was reduced
o 0.5 mg/kg, the next 2 doses were 2 mg/kg, and the
nal infusion was given on the day of transplant.
remedication included methylprednisolone 40 mg
ntravenously every 12 hours for 6 doses and benadryl
0 mg intravenously before each dose of ATG.
If no aGVHD occurred CSA was tapered over 4-8
eeks with the intent to discontinue by 2 to 4 months.
ngraftment
Daily blood counts were done until discharge with
one marrow aspirations at 3 months for surviving
atients and thereafter as clinically indicated. Granu-
ocyte engraftment was deﬁned as a count of 0.5 
09/L. The platelet count needed to be above 20 
09/L without transfusion for 3 days.
VHD
Acute GVHD was graded according to standard
riteria [27]. Grading was performed by physicians at
nset and during treatment, with later conﬁrmation and
ecording by data managers. pAcute GVHD was treated with prednisone or
ethylprednisolone initially while continuing CSA.
GVHD was treated with prednisone with or without
SA with introduction of other agents if response was
ncomplete.
tatistical Analysis
The distributions of time to events were plotted
n Kaplan-Meier curves and compared using the log
ank test with patients being censored for relapse for
stimation of nonrelapse mortality (NRH). For time
o onset of cGVHD patients were censored at the
ime of death, donor lymphocyte infusion (DLI), or
econd transplant. Analysis was performed on a
acintosh computer using GraphPad Prism software
GraphPad Corp., San Diego, CA). Values for P of
05-.1 are referred to as trends, and below .05 as
igniﬁcant.
ESULTS
ngraftment
All patients engrafted. Granulocytes recovered
aster after BCT than bone marrow transplant (BMT)
t a median of 15 days (range: 10-46) versus 20 days
range: 13-31), respectively (P  .02). Platelets en-
rafted in a median of 15 days (range: 0-34) after BCT
ompared with 25 days (range: 20-40) after BMT (P
0007).
VHD
The actuarial incidence of aGVHD grades II-IV was
1%  6%, after MRD SCT compared with 35% 
% after those from AD (P  .047; Figure 1a). The
gures for grade III-IV disease were 0% and 10% 
%, respectively (P  .09; Figure 1b).
Incidence of cGVHD at 2 years was 40%  9%
ith MRD versus 66%  9% with AD (P  NS;
igure 1c). Stem cell source from unrelated donors
ad no inﬂuence on GVHD (data not shown). At the
ime of analysis 2 of 32 patients developing cGVHD
fter their ﬁrst SCT remained on systemic therapy.
ransplant-related mortality (TRM)
One MRD and 1 AD SCT recipient died with-
ut relapse. One was in CR2 of ALL and died at 76
ays of posttransplant lymphoproliferative disease
PTLD). The second, with ALL in CR1, died 5
onths after SCT from pneumonitis. TRM was
%  2% for the combined group (Figure 2a).
here were no transplant-related deaths in the 17
atients 50 years old.
elapse
Relapse rate at 4 years was 29%  10% for ALL
atients and 17%  6% for those with AML (Figure
2
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SCT for Acute Leukemia in CR1 and CR2 817b). Three of 7 relapsing ALL patients survive having
chieved another remission after a second BCT, 2
rom the same donor, after conditioning with etopo-
ide 60 mg/kg and 800 cGy TBI. All 3 have had
igniﬁcant morbidity from cGVHD but have had a
onger remission after the second SCT than after the
rst. Transient responses were achieved in 1 ALL
atient with DLI and in 1 with DLI and imatinib
esylate. Of 6 relapsing AML patients 1 had radiation
Figure 1. Kaplan-Meier plots of GVHD. a, aGVHD grade
igure 2. Kaplan-Meier plots of a, relapse and b, transplant-related
cortality according to disease.herapy for a chloroma and 1 had chemotherapy but
ll died with leukemia.
isease-Free and Overall Survival
Projected disease-free survival (DFS) and overall
urvival (OS) at 3 years for AML is the same at 83%
%, and for ALL is 65%  10% and 78%  8%,
espectively (Figure 3a and 4a). For MRD SCT DFS
s 77%  9%, OS 87%  6%, for AD SCT the
espective ﬁgures are 71%  8% and 74%  8%
Figure 3b and 4b). OS and DFS in patients without
nd with high-risk features is 100% versus 71% 7%
P  .007) and 88%  8% versus 68%  7% (P 
04), respectively (Figures 3c and 4c).
ISCUSSION
Myeloablative regimens including TBI have never
een entirely superceded in SCT for acute leukemia.
ombinations of drugs alone, particularly BuCy,
ere developed in the hope that they could be
mployed by centers without TBI facilities and
ight avoid some of the long-term complications of
BI. Comparisons of BuCy2 (with Cy 120 mg/kg)
nd CyTBI show remarkably similar outcomes in
ML, whereas survival is better after CyTBI in
LL [7-14,16-19]. Combinations of etoposide and
BI may be at least as effective as the above regi-
ens in both ALL and AML [28-30].
Some single-center reports of combinations of 3
gents for acute leukemia transplants have been en-
b, aGVHD grades III-IV; c, cGVHD according to donor.ouraging [31,32]. In general, however, attempts to
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J. A. Russell et al.818educe relapse by increasing TBI dose or adding other
gents to standard regimens have largely been unsuc-
essful because of increased toxicity [33-36].
Many nonmyeloablative or reduced intensity reg-
mens have been designed to minimize the morbidity
nd mortality of allogeneic SCT and take advantage of
Figure 3. Kaplan-Meier plots of disease-free surFigure 4. Kaplan-Meier plots of overall survival by ahe GVL effect, particularly in older patients or those
ith comorbidities [39,40]. Despite some success in
educing TRM, so far the role of these regimens in
LL and AML has not been established. Our data
ive no indication that the FLUBUP/TBI regimen
hould be restricted to younger patients.
y a, disease, b, donor, and c, high-risk features., disease, b, donor, and c, high-risk features.
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SCT for Acute Leukemia in CR1 and CR2 819The comparisons referred to above of BuCy2 with
yTBI or VP16TBI were done with oral busulfan
ithout pharmacokinetic monitoring to achieve opti-
al drug exposures. Intravenous Bu has not been fully
ested in acute leukemia, but it is better tolerated and
ives more predictable exposures than oral Bu [20-
2,37]. The myeloablative combination of intravenous
u with Flu was developed because Flu is an effective
ntileukemic agent and better tolerated than Cy [38].
t was thought that the substitution of Flu for Cy
ight allow greater cytoreduction from higher Bu
xposures, but this does not seem to be the case [37].
Our previous studies with MRD SCT for AML in
R1 indicated that BCT produced better OS com-
ared with BMT but that quality of life was signiﬁ-
antly worse because of cGVHD [41]. Including ATG
n the GVHD prophylaxis may have reduced morbid-
ty and mortality from this cause at the expense of a
rend to more relapse [42]. The attempt to compen-
ate for this by adding 400 cGy TBI to the regimen
ppears to have had some success in AML, reducing
elapse without an increase in TRM [24]. Outcomes
re very similar to those reported by de Lima et al.
23] using a very similar Flu/Bu combination. Tacroli-
us and MTX was used for GVHD prevention with
orse ATG added for alternative donor SCT only.
ossibly the less aggressive GVHD prophylaxis for
RD allowed a greater GVL effect than was our
xperience with FLUBUP alone [42]. The critical
ssue might ultimately be that of long-term quality of
ife offered by these alternative approaches. It would
ake a randomized study to clarify this issue further.
The decision to investigate this regimen in ALL
as based on the more predictable pharmacokinetics
f intravenous compared with oral Bu and the ability
f both Bu and Flu to penetrate the nervous system.
e were, however, reluctant to drop TBI altogether
or this disease.
It is difﬁcult to compare outcomes even for early
cute leukemia with those in the literature because of
he heterogeneity of patient populations with respect
o prognostic factors. Outcomes of SCT may also be
mproving with time. Our study patients with high-
isk features in addition to age have a survival of about
0% at 3 years. All patients lacking these features are
live, an indication that survival at least was not com-
romised by early transplant for these patients. This
egimen may therefore give outcomes at least equiv-
lent to those incorporating full dose TBI [1,3,7-9,11-
3,15,29,30].
The higher TRM of allogeneic SCT with myeloa-
lative protocols has limited any survival advantage it
ay have had over alternatives such as autologous
ransplants and chemotherapy alone [1-3]. Although
ome studies, usually from single centers, have re-
orted TRM below 10% for early leukemia in adults,
ost multicenter and registry-based reports indicate lgures in the 20%-30% range for MRD transplants
1,3,7-9,11-13,15,29,30]. In the current series only 2
atients died without relapse. One of these was from
TLD, occurring before rituxan was available. In
ver 300 SCT in the last 6 years we have seen only
further death from PTLD where ATG was only
sed prophylactically. We have some evidence that
afety of this regimen could be improved further by
onitoring Bu pharmacokinetics to avoid toxic ex-
osures [37].
If survival is not demonstrably better with allo-
ransplant than alternative treatments, this option
hould generally not be chosen because of the long-
erm morbidity of cGVHD [4]. It is difﬁcult to com-
are reports of cGVHD, particularly with respect to
uality of life. However, It does seem that the inci-
ence of cGVHD and its complications are reduced
hen Thymoglobulin is added to the GVHD prophy-
axis [42-44]. Although a substantial number of our
atients still developed cGVHD after the ﬁrst SCT,
ost are now off treatment. Many patients can be
pared these effects and second transplants are feasible
or some who relapse. Thus, 3 of our ALL patients
elapsing beyond 2 years are in second remissions
onger than the ﬁrst ones but at the expense of mor-
idity from cGVHD. This is circumstantial evidence
or a GVL effect in at least in some patients with ALL,
or whom cGVHD may be the price to pay for long-
erm disease control.
Allogeneic transplantation in CR1 is generally ac-
epted as reasonable treatment for adults with high-
isk ALL [3]. Likewise SCT for AML is often reserved
or those with intermediate and high-risk karyotypes
1,2]. These recommendations are based on data in-
icating that TRM will be about 20%-30% for MRD
CT. There is more reluctance to use AD for CR1
atients because TRM has tended to be higher, al-
hough some reports indicate similar survival [45-49].
onditioning that could achieve low TRM and equiva-
ent results from AD and MRD might make allogeneic
CT in CR1 an option for more patients particularly if
he detrimental effects of cGVHD can be minimized.
ur policy is to offer SCT to all adults with acute
eukemia in CR1 apart from those with AMLwith good-
isk karyotypes. Although somemight beneﬁt by delay of
CT until relapse, not all patients achieve a second
emission, regardless of risk factors.
It will be some time before the long-term mor-
idity of this regimen can be evaluated, especially with
espect to second malignancies, but these are unlikely
o be more frequent than after full-dose TBI. Cur-
ently this combination appears to offer a well-toler-
ted alternative to more conventional myeloablative
egimens. If these results can be substantiated, the
egimen could also be considered for children in
hom the use of full dose TBI can have serious life-
ong consequences.
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